Deferred Tax Asset Valuation for Pre-IPO Companies: The Impact of Future Profitability Forecasts on DTA

The SFC’s December 2024 consultation on proposed amendments to the Listing Rules (specifically Chapter 9, which governs listing eligibility) has placed deferred tax asset (DTA) recognition squarely in the crosshairs of pre-IPO scrutiny. The consultation, which closed in March 2025, proposes that sponsors must provide a detailed assessment of an applicant’s ability to generate sufficient future taxable profits against which DTAs can be realised, moving beyond a simple reliance on historical profitability. This shift, coupled with the HKEX’s increasing focus on forward-looking financial information in listing documents (as per Guidance Letter GL86-16), means that a DTA valuation that was acceptable in a 2023 filing may now trigger a substantive review question. For a pre-IPO company, an overstated DTA artificially inflates net assets and earnings per share, creating a valuation gap that a sponsor cannot simply explain away. The core issue is no longer whether the DTA is technically correct under HKAS 12, but whether the underlying profit forecast is credible enough to satisfy the HKEX’s “sufficiency of operations” test under Listing Rule 8.05(3). This article dissects the mechanics of that intersection, providing a framework for CFOs and their advisors to stress-test their DTA positions before the sponsor’s due diligence begins.

The Structural Tension Between HKAS 12 and Listing Rule 8.05(3)

The accounting treatment of deferred tax assets under Hong Kong Financial Reporting Standards (HKFRS), specifically HKAS 12 Income Taxes, is permissive in theory but restrictive in practice for pre-IPO applicants. HKAS 12 permits the recognition of a DTA for deductible temporary differences and unused tax losses only to the extent that it is “probable” that future taxable profit will be available. This “probable” threshold, typically interpreted as greater than 50% likelihood, is a lower bar than the “virtually certain” standard required for DTAs arising from deductible temporary differences related to investments in subsidiaries, branches, and associates. The critical operational detail, however, is that the entity must have convincing evidence that sufficient taxable profit will exist.

The Sponsor’s Burden Under Proposed Rule Changes

The SFC’s December 2024 consultation paper, Proposed Amendments to the Listing Rules Relating to Listing Eligibility and Suitability, explicitly targets the quality of forward-looking financial information. Paragraph 45 of the consultation paper states that sponsors must now “evaluate the reasonableness of the assumptions underlying the applicant’s profit forecast, particularly those supporting the recognition of significant deferred tax assets.” This is a direct escalation from the previous standard, which largely accepted historical tax payment patterns as sufficient evidence. Under the proposed framework, a sponsor must document a specific, time-bound business plan—typically covering the period until the DTA is fully utilised—and demonstrate that the plan is consistent with the company’s historical performance and industry trends. A failure to do so results in a negative sponsor’s declaration, which is a fatal impediment to the listing application.

The Two-Year Forecast Horizon as a De Facto Rule

While HKAS 12 does not prescribe a specific forecast horizon, HKEX Listing Decision LD43-3 (2012) provides a practical benchmark. In that decision, the HKEX accepted a DTA recognition based on a two-year profit forecast, provided the forecast was supported by signed contracts and a clear pipeline of orders. The implicit logic is that forecasts beyond two years for a pre-IPO company—which has not yet established a public market track record—are inherently speculative. The HKEX’s Listing Division will therefore scrutinise any DTA that relies on taxable profits expected more than 24 months from the latest balance sheet date. For a company with accumulated tax losses of HKD 50 million, for example, and a projected annual taxable profit of HKD 20 million, the full utilisation period is 2.5 years. That 6-month overhang beyond the two-year window will require specific, verifiable evidence—such as a signed off-take agreement or a committed credit facility—to avoid a listing objection.

Quantifying the Impact: DTA as a Lever on Valuation Multiples

The balance sheet impact of a misvalued DTA is not merely an accounting adjustment; it is a direct lever on the pre-IPO valuation multiple. A company with a net profit of HKD 100 million and a DTA of HKD 30 million is reporting a post-tax profit that is inflated by the DTA’s reversal effect. If that DTA is subsequently written off, the company’s net profit drops by HKD 30 million, and the valuation multiple—say 15x P/E—applied to that lower base results in a HKD 450 million reduction in equity value.

The Earnings Per Share Distortion

For pre-IPO companies, the DTA directly affects the basic earnings per share (EPS) figure disclosed in the prospectus. Under Listing Rule 11.10, the profit forecast in the listing document must be based on the same accounting policies as the historical financial statements. If a DTA is recognised in the historical period but the profit forecast used to support it is not explicitly linked to the same assumptions, the sponsor faces a reconciliation problem. Consider a company with 100 million shares outstanding: a HKD 20 million DTA recognised in Year 1 inflates EPS by HKD 0.20. If the market prices the IPO at 20x forward EPS, that HKD 0.20 translates to an additional HKD 4.00 per share in the offer price. For a 25% public float, this represents HKD 100 million in proceeds that are contingent on the DTA’s validity. The sponsor’s due diligence must therefore confirm that the profit forecast used for the DTA is the same forecast used for the IPO pricing.

The Net Asset Value Floor

The DTA also inflates net asset value (NAV), which serves as the floor for certain valuation methodologies, particularly for financial institutions and property companies. Under HKAS 12, a DTA is classified as a non-current asset. A company with total assets of HKD 500 million and a DTA of HKD 40 million has 8% of its asset base tied to a future tax benefit. If the HKEX’s Listing Division questions the recoverability of that DTA, the company may be forced to reclassify it as a current asset or, worse, write it down entirely. This write-down reduces NAV by HKD 40 million, which, under a price-to-book valuation of 1.2x, reduces equity value by HKD 48 million. For a company seeking a HKD 1 billion valuation, this is a 4.8% haircut.

Sector-Specific Vulnerabilities: Where DTA Risk Concentrates

The risk profile of DTA recognition is not uniform across industries. The HKEX’s 2023 Report on the Review of Listing Applicants’ Financial Information identified that technology, biotech, and renewable energy companies were disproportionately affected by DTA-related queries. These sectors share a common characteristic: they generate significant tax losses in their early years due to high R&D expenditure and capital investment, and their profitability forecasts are inherently more volatile.

Biotech and the “No Revenue” Trap

For biotech companies listing under Chapter 18A of the Listing Rules, which permits listing without revenue, the DTA issue is particularly acute. A biotech company with no approved product has no historical taxable profit. Its DTA can only be supported by a forecast of future profitability, which is entirely dependent on regulatory approval timelines. The HKEX’s Guidance Letter GL92-18 explicitly states that for Chapter 18A applicants, the sponsor must “provide a detailed analysis of the probability of future taxable profits, including the impact of regulatory milestones.” A DTA of HKD 100 million for a biotech company with a Phase 3 trial that is 18 months from completion is therefore speculative. The sponsor must show that the trial’s success probability—typically 50-60% for Phase 3—is sufficient to meet the “probable” threshold. If the probability is lower, the DTA must be written down.

Technology Companies and the R&D Super-Deduction

Hong Kong’s two-tiered profits tax regime, introduced in 2018, allows a 300% tax deduction for qualifying R&D expenditure. For a technology company spending HKD 50 million annually on R&D, this creates a deductible temporary difference of HKD 150 million. The resulting DTA is large relative to the company’s asset base. The critical issue is that this deduction is a timing difference; it reverses as the company becomes profitable. The HKEX will require the sponsor to demonstrate that the company’s revenue growth trajectory is sufficient to absorb these deductions within a reasonable period. A company projecting HKD 200 million in revenue by Year 3, with a 20% pre-tax margin, generates HKD 40 million in taxable profit per year. To absorb a HKD 150 million DTA, it would take 3.75 years. That period exceeds the two-year forecast horizon, triggering the need for additional evidence.

Practical Structuring: How CFOs Can Defend Their DTA Position

The most effective defence of a DTA position is proactive documentation, not reactive explanation. A CFO preparing for a 2025-2026 listing should begin the DTA stress-testing process at least 12 months before the intended filing date. This involves three distinct workstreams.

Workstream 1: The Profit Forecast Sensitivity Analysis

The sponsor will require a base-case, upside, and downside scenario for the profit forecast. The DTA must be supportable under the base case. The CFO should commission a sensitivity analysis that shows the DTA’s recoverability under a 10% revenue shortfall and a 5% margin compression. If the DTA is not recoverable under the downside scenario, the sponsor will likely require a partial write-down. The analysis should be documented in a formal memorandum, signed off by the company’s audit committee, and shared with the sponsor’s due diligence team. This memo should cite specific assumptions, such as the expected utilisation period, the discount rate applied (if any), and the tax jurisdiction’s loss carry-forward rules. For Hong Kong, tax losses can be carried forward indefinitely under Section 19C of the Inland Revenue Ordinance (Cap. 112), but only against profits from the same trade or business.

Workstream 2: The Contractual Backing Requirement

The HKEX’s Listing Division has a strong preference for DTA support that is grounded in signed contracts rather than pipeline projections. For a company with HKD 30 million in DTA, the CFO should identify at least HKD 20 million in future taxable profit that is backed by signed sales agreements or committed purchase orders. These contracts should be for delivery within the next 12-18 months. The remaining HKD 10 million can be supported by a forecast, but that forecast must be based on a demonstrable historical conversion rate. For example, if the company has a 70% conversion rate from qualified leads to signed contracts over the past three years, that rate can be applied to the current pipeline to support the forecast. The sponsor will verify this conversion rate against the company’s CRM data.

Workstream 3: The Tax Planning Strategy

A DTA can also be supported by a specific tax planning strategy that accelerates taxable profit. For example, a company can elect to accelerate revenue recognition for tax purposes by changing its billing terms or by utilising a group relief election under Section 19 of the Inland Revenue Ordinance. This strategy must be documented and approved by the board before the listing application. The HKEX will consider this strategy as “convincing evidence” under HKAS 12, provided it is legally enforceable and the company has the operational capacity to execute it. A common approach is to shift a profitable subsidiary’s revenue into the loss-making entity through a transfer pricing arrangement, provided the arrangement complies with the OECD’s arm’s length principle. The company should engage a tax advisor to issue a formal opinion on the strategy’s validity.

Actionable Takeaways

1. Initiate a DTA stress-test at least 12 months before the intended A1 filing to allow time for corrective adjustments, as the SFC’s December 2024 consultation paper on Listing Rule amendments will likely make sponsor scrutiny of profit forecasts more rigorous by mid-2025.
2. Ensure that at least 70% of the DTA’s value is supported by signed contracts or committed orders with delivery within 12 months, as the HKEX’s Listing Division (per LD43-3) favours contractual backing over pipeline projections for forecasts beyond 24 months.
3. Commission a three-scenario sensitivity analysis (base, upside, downside) for the profit forecast, and document the DTA’s recoverability under the base case in a formal audit committee memorandum.
4. For companies in sectors with long R&D cycles (biotech, technology), explicitly link the DTA’s utilisation period to specific regulatory or commercial milestones, and provide a probability-weighted analysis for each milestone.
5. Consider implementing a board-approved tax planning strategy, such as a group relief election or a transfer pricing realignment, to generate taxable profit within the two-year forecast horizon and document the strategy’s legal basis.